Francis P Worden

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007
    Francis P Worden
    Department of Internal Medicine, Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan 48109 0848, USA
    Cancer 107:319-27. 2006
  2. pmc Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion
    Francis P Worden
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Laryngoscope 119:1510-7. 2009
  3. pmc Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number
    Francis P Worden
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 26:3138-46. 2008
  4. ncbi request reprint Controversies in the management of oropharynx cancer
    Francis P Worden
    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 6:707-14. 2008
  5. doi request reprint Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer
    Bryan J Schneider
    Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
    Clin Lung Cancer 11:223-7. 2010
  6. pmc EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer
    Bhavna Kumar
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Comprehensive Cancer Center Head and Neck Cancer Program, Ann Arbor, MI 48109, USA
    J Clin Oncol 26:3128-37. 2008
  7. pmc Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results
    Felix Y Feng
    Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    J Clin Oncol 28:2732-8. 2010
  8. ncbi request reprint Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer
    Mary Feng
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Radiother Oncol 77:32-8. 2005
  9. pmc Chemotherapy alone for organ preservation in advanced laryngeal cancer
    Vasu Divi
    Department of Otolaryngology Head and Neck Surgery, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA
    Head Neck 32:1040-7. 2010
  10. ncbi request reprint Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer
    Alexander Lin
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 63:1413-8. 2005

Detail Information

Publications32

  1. ncbi request reprint A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007
    Francis P Worden
    Department of Internal Medicine, Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan 48109 0848, USA
    Cancer 107:319-27. 2006
    ..To validate these results and to determine the feasibility of this combination, a Phase II study was conducted by the Southwest Oncology Group (SWOG S0007)...
  2. pmc Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion
    Francis P Worden
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Laryngoscope 119:1510-7. 2009
    ..Patients were treated with chemoradiation after a >50% primary tumor response to one cycle of neoadjuvant chemotherapy (IC). We analyzed outcomes for T4 patients with cartilage invasion from both studies...
  3. pmc Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number
    Francis P Worden
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 26:3138-46. 2008
    ..To test induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) or surgery/radiotherapy (RT) for advanced oropharyngeal cancer and to assess the effect of human papilloma virus (HPV) on response and outcome...
  4. ncbi request reprint Controversies in the management of oropharynx cancer
    Francis P Worden
    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 6:707-14. 2008
    ..Unfortunately, these and other questions concerning the management of locally advanced oropharyngeal cancers are outstanding. Hence, it is critical that eligible patients are screened for and encouraged to participate in clinical trials...
  5. doi request reprint Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer
    Bryan J Schneider
    Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
    Clin Lung Cancer 11:223-7. 2010
    ..This trial was designed to evaluate irinotecan/cisplatin plus maintenance imatinib in patients with c-Kit-positive disease (the transmembrane receptor c-Kit is the product of the c-KIT protooncogene)...
  6. pmc EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer
    Bhavna Kumar
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Comprehensive Cancer Center Head and Neck Cancer Program, Ann Arbor, MI 48109, USA
    J Clin Oncol 26:3128-37. 2008
    ..To prospectively identify markers of response to therapy and outcome in an organ-sparing trial for advanced oropharyngeal cancer...
  7. pmc Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results
    Felix Y Feng
    Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    J Clin Oncol 28:2732-8. 2010
    ..To assess clinical and functional results of chemoradiotherapy for oropharyngeal cancer (OPC), utilizing intensity-modulated radiotherapy (IMRT) to spare the important swallowing structures to reduce post-therapy dysphagia...
  8. ncbi request reprint Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer
    Mary Feng
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Radiother Oncol 77:32-8. 2005
    ..Predictive factors for local-regional (LR) failures after parotid-sparing, Intensity modulated (IMRT) or 3D conformal radiotherapy for head and neck (HN) cancers were assessed...
  9. pmc Chemotherapy alone for organ preservation in advanced laryngeal cancer
    Vasu Divi
    Department of Otolaryngology Head and Neck Surgery, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA
    Head Neck 32:1040-7. 2010
    ....
  10. ncbi request reprint Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer
    Alexander Lin
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 63:1413-8. 2005
    ..Weight loss caused by acute mucositis and dysphagia is common during concurrent chemoirradiation (chemo-RT) of head-and-neck (HN) cancer. The metabolic consequences of weight loss during chemo-RT were investigated...
  11. pmc Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking
    Bhavna Kumar
    Department of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 69:S109-11. 2007
    ..Smoking cessation and strategies to target EGFR may be useful adjuncts for therapy to improve outcome in the cases with the poorest biomarker profile...
  12. ncbi request reprint Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer
    Aaron M Allen
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Head Neck 29:137-42. 2007
    ..Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC)...
  13. pmc HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans
    Jessica H Maxwell
    University of Michigan Medical School, The University of Michigan Health System and Comprehensive Cancer Center, Ann Arbor, MI, USA
    Head Neck 32:562-7. 2010
    ..The HPV, p16, and EBV status was examined in current University of Michigan patients with NPC...
  14. pmc Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence
    Jessica H Maxwell
    Departments of Otolaryngology Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Clin Cancer Res 16:1226-35. 2010
    ....
  15. pmc Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer
    Joshua A Bauer
    Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 69:S106-8. 2007
    ..Cisplatin resistance remains a barrier to organ-sparing and survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). Targeted therapies to overcome cisplatin-resistant HNSCC are being developed...
  16. ncbi request reprint Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer 109:2315-22. 2007
    ..The pharmacokinetics of ifosfamide and CYP3A measurements observed are reported...
  17. pmc Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status
    Matthew E Spector
    Departments of Otolaryngology Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
    Head Neck 34:1727-33. 2012
    ..Despite better prognosis, there is a group of oropharyngeal squamous cell carcinoma (SCC) human papillomavirus (HPV)+ patients who experience treatment failure and succumb to distant metastasis...
  18. doi request reprint Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, J 321, New York, NY 10021, USA
    Invest New Drugs 27:571-8. 2009
    ....
  19. pmc Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: are we changing life expectancy?
    Matthew E Spector
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
    Laryngoscope 122:1507-11. 2012
    ..To determine if the various imaging modalities for distant metastasis (DM) diagnosis alters life expectancy in head and neck squamous cell carcinoma (HNSCC)...
  20. pmc High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma
    Laura Stanbery
    The Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Transl Oncol 3:239-45. 2010
    ..00094). SEPT9_v1 is highly expressed in HNSCC, and a high expression of SEPT9_v1 is associated with poor clinical outcomes. These data indicate that SEPT9_v1 warrants additional investigation as a potential biomarker for HNSCC...
  21. ncbi request reprint Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing
    Avraham Eisbruch
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 59:28-42. 2004
    ..Locoregional (LR) failures near the base of the skull, and their relationships to the targets in the high neck, were examined in a series of patients who underwent intensity-modulated radiotherapy (IMRT) for head-and-neck cancer...
  22. pmc Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy
    Bryan J Schneider
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan, USA
    J Thorac Oncol 3:1454-9. 2008
    ..To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer after failure of platinum-based therapy...
  23. pmc Head and neck squamous cell carcinoma in pregnant women
    Anna M Eliassen
    Department of Otolaryngology Head and Neck Surgery, The University of Michigan, Ann Arbor, Michigan, USA
    Head Neck 35:335-42. 2013
    ..The aim of this study was to investigate oral cancer in pregnant women, a rare but therapeutically challenging patient subset...
  24. doi request reprint Osteocutaneous free tissue transplantation for mandibular osteoradionecrosis
    Shamir P Chandarana
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan 48109 0312, USA
    J Reconstr Microsurg 29:5-14. 2013
    ..To describe the success rate, complications, and functional outcomes of patients who are treated with osteocutaneous free tissue transplantation for grade 4 mandibular osteoradionecrosis (ORN)...
  25. doi request reprint Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma
    Christina I Tsien
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan
    Head Neck 35:1323-30. 2013
    ....
  26. doi request reprint A phase II study of imatinib in patients with advanced anaplastic thyroid cancer
    Huan T Ha
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Thyroid 20:975-80. 2010
    ..Imatinib inhibits tyrosine kinase activity of Bcr-ABL and PDGF. We hypothesize that patients with ATC that over-expresses PDGF receptors or cABL will respond to imatinib...
  27. ncbi request reprint Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma
    Francis P Worden
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 23:105-12. 2005
    ..The purpose of this study was to compare the efficacy and toxicity of doxorubicin with high-dose (HD) ifosfamide or standard-dose (SD) ifosfamide in patients with STS...
  28. doi request reprint Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma
    Irina Y Dobrosotskaya
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Endocr Pract 17:e59-62. 2011
    ..To describe successful long-term tumor control in metastatic adrenocortical carcinoma, a relatively rare tumor with limited treatment options outside of surgery...
  29. ncbi request reprint Use of warfarin in the patient with cancer
    Joanna Maudlin Pangilinan
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    J Support Oncol 5:131-6. 2007
  30. pmc Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution
    Erin M Lin
    Department of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan
    Skull Base 20:61-7. 2010
    ..It is possible that up-front radiation or chemoradiation will lead to better local control rates, though surgery remains a mainstay of treatment. In all cases, the cervical nodes should be addressed with primary treatment...
  31. ncbi request reprint Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma
    Gavin C Mackie
    Department of Radiological Sciences, St Jude Children s Research Hospital, 332 North Lauderdale, Mail Stop 752, Memphis, Tennessee 38105 2794, USA
    J Clin Endocrinol Metab 91:2665-71. 2006
    ..Adrenocortical carcinomas are uncommon, and their evaluation by [(18)F]fluorodeoxyglucose positron emission tomography (FDG PET) has not been well evaluated...
  32. doi request reprint Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
    J Clin Oncol 26:4708-13. 2008
    ..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer...